Literature DB >> 25538169

Outpatient parenteral antimicrobial therapy and antimicrobial stewardship: challenges and checklists.

M Gilchrist1, R A Seaton2.   

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) has become, for many countries, an established form of healthcare delivery. At the same time, there have been calls to ensure the prudent use of the existing antimicrobial armamentarium. For OPAT, this presents a dilemma. On one hand, stewardship principles look for the most effective agent with minimal collateral effects. In OPAT, whilst the aims of the service are similar, convenience of dosing to optimize early hospital discharge or admission avoidance may take precedence over an agent's spectrum of activity. This brief article aims to highlight the importance and explore the challenges of antimicrobial stewardship in the context of OPAT. Within the UK, the safe and effective use of antimicrobials is modelled around the IDSA/Society for Healthcare Epidemiology of America stewardship practice guidelines with local customization where appropriate. Current UK stewardship practice principles were compared with published good practice recommendations for OPAT to identify how OPAT could support the broader antimicrobial stewardship agenda. It is essential that antimicrobial stewardship teams should understand the challenges faced in the non-inpatient setting and the potential benefits/lower risks associated with avoided admission or shortened hospital stay in this population. Within its limitations, OPAT should practise stewardship principles, including optimization of intravenous to oral switch and the reporting of outcomes, healthcare-associated infections and re-admission rates. OPAT should report to the antimicrobial stewardship team. Ideally the OPAT team should be formally represented within the stewardship framework. A checklist has been proposed to aid OPAT services in ensuring they meet their stewardship agenda.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ambulatory care; clinical governance; intravenous therapy

Mesh:

Substances:

Year:  2014        PMID: 25538169     DOI: 10.1093/jac/dku517

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  30 in total

1.  Outpatient Parenteral Antimicrobial Therapy in Vulnerable Populations-- People Who Inject Drugs and the Homeless.

Authors:  Alison Beieler; Amalia Magaret; Yuan Zhou; Anneliese Schleyer; Anna Wald; Shireesha Dhanireddy
Journal:  J Hosp Med       Date:  2019-02       Impact factor: 2.960

Review 2.  Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?

Authors:  Ester Steffens; Charlotte Quintens; Inge Derdelinckx; Willy E Peetermans; Johan Van Eldere; Isabel Spriet; Annette Schuermans
Journal:  Infection       Date:  2018-11-15       Impact factor: 3.553

3.  Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy.

Authors:  L Herrera-Hidalgo; L E López-Cortes; R Luque-Márquez; J Gálvez-Acebal; A de Alarcón; L F López-Cortes; A Gutiérrez-Valencia; M V Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Authors:  Andreas Engert; Carlo Balduini; Anneke Brand; Bertrand Coiffier; Catherine Cordonnier; Hartmut Döhner; Thom Duyvené de Wit; Sabine Eichinger; Willem Fibbe; Tony Green; Fleur de Haas; Achille Iolascon; Thierry Jaffredo; Francesco Rodeghiero; Gilles Salles; Jan Jacob Schuringa
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

5.  OPAT in Switzerland: single-center experience of a model to treat complicated infections.

Authors:  Andrea Erba; Michelle Beuret; Mary-Louise Daly; Nina Khanna; Michael Osthoff
Journal:  Infection       Date:  2019-12-11       Impact factor: 3.553

6.  Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.

Authors:  Rachel S Britt; Mary T LaSalvia; Simi Padival; Parth Patel; Christopher McCoy; Monica V Mahoney
Journal:  Open Forum Infect Dis       Date:  2019-11-19       Impact factor: 3.835

7.  Prescribing Patterns and Patient Outcomes for Bone and Joint Infections Treated with Cefazolin and Probenecid: A Retrospective Observational Study.

Authors:  Marci E Dearing; Sarah V Burgess; Valerie Murphy; Samuel Campbell; Lynn Johnston; Tasha D Ramsey
Journal:  Can J Hosp Pharm       Date:  2020-06-01

8.  Measuring antimicrobial prescribing quality in outpatient parenteral antimicrobial therapy (OPAT) services: development and evaluation of a dedicated national antimicrobial prescribing survey.

Authors:  N Deborah Friedman; Seok M Lim; Rodney James; Robyn Ingram; Mary O'Reilly; James G D Pollard; Sonia Koning; Catherine George; Arjun Rajkhowa; Douglas F Johnson; Kirsty L Buising
Journal:  JAC Antimicrob Resist       Date:  2020-08-06

Review 9.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

10.  Evaluating the safety and effectiveness of a nurse-led outpatient virtual IV vancomycin monitoring clinic: a retrospective cohort study.

Authors:  Kate S Grattan; Mohamed Mohamed Ali; Seyed M Hosseini-Moghaddam; Hayley J I Gilmour; Gregory P Crunican; Erica Hua; Kelly A Muhsin; Rochelle Johnstone; Lise C Bondy; Megan K Devlin; Sarah Shalhoub; Sameer Elsayed; Michael S Silverman
Journal:  JAC Antimicrob Resist       Date:  2021-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.